# Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

> **NCT03755947** · PHASE2 · COMPLETED · sponsor: **Grupo Cooperativo de Hemopatías Malignas** · enrollment: 3 (actual)

## Conditions studied

- B-Cell Chronic Lymphocytic Leukemia
- B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Obinutuzumab
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03755947
- **Lead sponsor:** Grupo Cooperativo de Hemopatías Malignas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-02-01
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2021-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03755947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03755947, "Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03755947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*